Severe Asthma Management
Publication Date: October 1, 2019
Key Points
Key Points
Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.
Treatment
...atment
.... Recommendations for the Management...
...gest an anti-IL-5 strategy as add-on therapy...
...hat a blood eosinophil cut-point ≥150 µL...
...g a blood eosinophil cut-off ≥260...
...a FENO cut-off ≥19.5 ppb to identify adolescent...
...dren, adolescents and adults with severe...
...uggest a trial of macrolide treatment to...
...nst the use of chronic macrolide treatme...
...gest dupilumab as add-on therapy for adult pa...
...le 2. Monoclonal Antibodies for Severe...